Browser storage is unavailable. Keep this page open and export your collection before leaving.
Shield Bio
Shield Bio is a precision medicine company with a proprietary platform that enables reliable nanopore sequencing in under a minute, in a clinical setting. It is focused on bringing 3rd generation or "nanopore" sequencing into clinical use to deliver on the promise of precision medicine. Shield is initially using the technology to improve the
Overview
Shield Bio is a precision medicine company with a
proprietary platform that enables reliable nanopore
sequencing in under a minute, in a clinical setting. It is
focused on bringing 3rd generation or "nanopore"
sequencing into clinical use to deliver on the promise of
precision medicine. Shield is initially using the technology to
improve the treatment of infectious disease and address the
unmet clinical need of sepsis, which kills 300,000 people a
year in the US alone.
Founders & team
Previously TL Biolabs, Shield Diagnostics
News & product activity
Sources & observations
Maturity: Not assessed · 3 of 6 areas documented
Source-based assessment · automated evidence rules
The source reports an inactive or acquired company; current product identity needs review.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-08
- Product visualsNot documented
- Founders & originsTeam information
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2016 Q3 (quarter only)





